Molecular Nutrition & Food Research · 2015 · 78 citations · 39 references
MedicineOncologyPharmacologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingCell Signaling DisruptionColorectal CancerGrowth Factor SignalingOncogenic Signaling PathwaysEgfr InhibitionEpidermal Growth Factor Receptor InhibitionEpidermal Growth Factor Receptor Signaling
SCOPE: We studied the effects and mechanism of 2-(3,4-dihydroxyphenil)ethanol (or hydroxytyrosol, HT), a polyphenol from extra virgin olive oil, investigating the regulation of epidermal growth factor receptor (EGFR) expression in colon tumour cells. METHODS AND RESULTS: We demonstrate that HT significantly downregulates EGFR expression in human colorectal adenocarcinoma cells HT-29, CaCo2, and WiDr, and in HT-29 xenografts. HT accelerates EGFR degradation by reducing its half-life. Specifically, HT induces EGFR ubiquitination that is mediated by phosphorylation at pY1045, the docking site for Cbl, thereby enabling receptor ubiquitination and degradation. Pretreatment with either the lysosomal inhibitor chloroquine, or the proteasomal inhibitor MG132 blocks HT-induced EGFR downregulation. In colon cancer cells, EGFR downregulation by HT is associated with reduced cell proliferation. Tumour growth and EGFR expression levels are also decreased by HT treatment in HT-29 xenograft. CONCLUSION: We conclude that HT downregulates EGFR expression via lysosomal and proteasomal degradation, activated by HT-induced EGFR phosphorylation at pY1045 and increased Cbl activity. Cbl activation induces, in turn, EGFR ubiquitination. Our results reveal a new mechanism for HT's antitumour effects that may be important for colon tumour prevention and treatment.
39
Eric Van Cutsem, Marc Peeters, Salvatore Siena et al. · Journal of Clinical Oncology · 2007 · 2K citations
Medicine, Oncology, Pharmacology +14
Cetuximab for the Treatment of Colorectal Cancer
Derek J. Jonker, Chris J. O’Callaghan, Christos S. Karapetis et al. · New England Journal of Medicine · 2007 · 1.8K citations · Full text
Medicine, Oncology, Pharmacology +17
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Luis A. Díaz, Richard T. Williams, Jian Wu et al. · Nature · 2012 · 1.7K citations · Full text
Cetuximab in the treatment of colorectal cancer.
Richard M. Goldberg, Alan P. Venook, Richard L. Schilsky · PubMed · 2004 · 1.5K citations
Medicine, Oncology, Pharmacology +10